For example, IL-2 therapy given twice daily for three consecutive days starting 5 days prior to surgery was shown to improve 5-year disease-free survival and OS in patients with pancreatic cancer [59] and reduced the frequency of disease progression in patients with colorectal cancer [60], compared with placebo. The gene discussed is IL2; the disease is familial pancreatic carcinoma.